Associations between PPARG polymorphisms and the risk of essential hypertension

• Published in: PloS one Vol. 12; no. 7; p. e0181644
• Main Authors: Cai, Gaojun, Zhang, Xinyong, Weng, Weijin, Shi, Ganwei, Xue, Sheliang, Zhang, Bifeng
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 20-07-2017; Public Library of Science (PLoS)
• Subjects: Biology and Life Sciences; Blood; Blood pressure; Cardiology; Cardiovascular disease; Carriers; Confidence intervals; Diabetes; Essential Hypertension; Genes; Genetic aspects; Genetic Association Studies; Genetic polymorphisms; Genetic Predisposition to Disease; Hospitals; Humans; Hypertension; Hypertension - ethnology; Hypertension - genetics; Hypertension - physiopathology; Medical ethics; Medicine and Health Sciences; Meta-analysis; Metabolic syndrome; Minority & ethnic groups; Pathogenesis; Patient outcomes; People and Places; Peroxisome proliferator-activated receptors; Physical Sciences; Physiological aspects; Polymorphism; Polymorphism, Genetic; PPAR gamma - metabolism; Research and Analysis Methods; Risk analysis; Risk factors; Search methods; Studies; Thiazolidinediones; Vasoactive intestinal peptide
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0181644

Peroxisome proliferator-activated receptor gamma (PPARG) plays an important role in the pathogenesis and maintenance of essential hypertension (EH). It has been suggested that polymorphisms of PPARG are associated with the risk of EH. However, findings to date remain controversial. To elucidate the associations between the PPARG Pro12Ala and C161T polymorphisms and EH risk, a meta-analysis was carried out.
A comprehensive literature search of PubMed, Embase, CNKI (Chinese National Knowledge Infrastructure), VIP and Wanfang databases was conducted. The pooled odds ratios (ORs) and 95% confidence interval (CI) were calculated to estimate the size of the effect using the random-effects model. At the same time, the pooled standardized mean difference (SMD) with 95% CI was used for the meta-analysis of the PPARG Pro12Ala polymorphism and blood pressure.
Finally, Fifteen papers (seventeen studies) including 4,151 cases and 4,997 controls to evaluate the association of the PPARGPro12Ala polymorphism and EH risk, were included in this study. Overall, the results suggested that Ala allele was associated with the decreased EH risk (for allelic model, OR = 0.757, 95%CI: 0.624-0.918, P = 0.005; for dominant model, OR = 0.771, 95%CI: 0.627-0.946, P = 0.013). The subgroup analysis stratified by ethnicity showed that the significant association between the PPARG Pro12Ala polymorphism and EH was only detected in the Asian subgroup. There was no difference in blood pressure values between Ala carriers and non-carriers. For the C161T polymorphism, only 5 studies comprising 1,118 cases and 1,357 controls met the inclusion criteria. The overall results showed that the PPARG C161T polymorphism was not associated with the risk of EH. But in the subgroup analysis, we found that the PPARG C161T polymorphism significantly associated with the risk of EH in the Asian subgroup (for allelic model, OR = 0.719, 95% CI: 0.537-0.963, P = 0.027; for dominant model, OR = 0.653, 95% CI: 0.439-0.972, P = 0.036).
Our meta-analysis suggested that the PPARG polymorphisms might be associated with the risk of EH.